Current Report Filing (8-k)

Date : 06/03/2019 @ 8:27PM
Source : Edgar (US Regulatory)
Stock : Fulgent Genetics Inc (FLGT)
Quote : 11.83  0.23 (1.98%) @ 4:59AM
Fulgent Genetics share price Chart

Current Report Filing (8-k)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  May 30, 2019

 

FULGENT GENETICS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

001-37894

 

81-2621304

(State or other jurisdiction of

incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

 

4978 Santa Anita Avenue, Suite 205

Temple City, California

 

91780

(Address of Principal Executive Offices)

 

(Zip Code)

 

(626) 350-0537

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

FLGT

 

The Nasdaq Stock Market 
(Nasdaq Global Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

 


 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On May 30, 2019, Fulgent Genetics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) at its offices in El Monte, California. An aggregate of 18,287,400 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting as of April 5, 2019, the record date for the Annual Meeting. Of these shares, 16,295,709 shares were present in person or by proxy at the Annual Meeting, constituting a quorum of 89%. The Company’s stockholders considered and voted on two proposals at the Annual Meeting, and cast their votes on each such proposal as set forth below.

 

Proposal 1 : To elect four directors, each to serve a one-year term until the 2020 annual meeting of the Company’s stockholders and until his successor is duly elected and qualified or until his earlier resignation or removal. The results of the voting on Proposal 1 were as follows:

 

Directors

 

For

 

 

Withheld

 

 

Broker Non-Votes

 

Ming Hsieh

 

 

12,740,870

 

 

 

78,500

 

 

 

3,476,339

 

John Bolger

 

 

12,739,870

 

 

 

79,500

 

 

 

3,476,339

 

James J. Mulay (Mulé), I.Ph.D.

 

 

12,740,870

 

 

 

78,500

 

 

 

3,476,339

 

Yun Yen, M.D., Ph.D., F.A.C.P.

 

 

12,731,751

 

 

 

87,619

 

 

 

3,476,339

 

 

 

Proposal 2 : To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019. The results of the voting on Proposal 2 were as follows:

 

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

 

16,189,660

 

 

 

86,282

 

 

 

19,767

 

 

 

-

 

 

 

 


 


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Date: June 3, 2019

FULGENT GENETICS, INC.

 

 

 

 

 

 

 

By:

/s/ Paul Kim

 

 

Name: Paul Kim

 

 

Title: Chief Financial Officer

 

 

 

 

Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart

1 Year : From Dec 2018 to Dec 2019

Click Here for more Fulgent Genetics Charts.

Fulgent Genetics (NASDAQ:FLGT)
Intraday Stock Chart

Today : Sunday 8 December 2019

Click Here for more Fulgent Genetics Charts.

Latest FLGT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191209 03:45:51